Literature DB >> 22206998

Antioxidants in Down syndrome.

Ira T Lott1.   

Abstract

Individuals with Down syndrome (DS) have high levels of oxidative stress throughout the lifespan. Mouse models of DS share some structural and functional abnormalities that parallel findings seen in the human phenotype. Several of the mouse models show evidence of cellular oxidative stress and have provided a platform for antioxidant intervention. Genes that are overexpressed on chromosome 21 are associated with oxidative stress and neuronal apoptosis. The lack of balance in the metabolism of free radicals generated during processes related to oxidative stress may have a direct role in producing the neuropathology of DS including the tendency to Alzheimer disease (AD). Mitochondria are often a target for oxidative stress and are considered to be a trigger for the onset of the AD process in DS. Biomarkers for oxidative stress have been described in DS and in AD in the general population. However, intervention trials using standard antioxidant supplements or diets have failed to produce uniform therapeutic effect. This chapter will examine the biological role of oxidative stress in DS and its relationship to abnormalities in both development and aging within the disorder. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22206998      PMCID: PMC3408054          DOI: 10.1016/j.bbadis.2011.12.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  112 in total

Review 1.  Down's syndrome: a pathology involving the lack of balance of reactive oxygen species.

Authors:  J Kedziora; G Bartosz
Journal:  Free Radic Biol Med       Date:  1988       Impact factor: 7.376

Review 2.  Beta-amyloid, oxidative stress and down syndrome.

Authors:  Ira T Lott; Elizabeth Head; Eric Doran; Jorge Busciglio
Journal:  Curr Alzheimer Res       Date:  2006-12       Impact factor: 3.498

3.  Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines.

Authors:  Elizabeth Head; Viorela Pop; Floyd Sarsoza; Rakez Kayed; Tina L Beckett; Christa M Studzinski; Jennifer L Tomic; Charles G Glabe; M Paul Murphy
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Okadaic acid induces apoptosis in Down syndrome fibroblasts.

Authors:  G Dogliotti; E Galliera; E Dozio; E Vianello; R E Villa; F Licastro; I Barajon; M M Corsi
Journal:  Toxicol In Vitro       Date:  2009-12-13       Impact factor: 3.500

5.  Plasma amino acids and neopterin in healthy persons with Down's syndrome.

Authors:  A W Coppus; D Fekkes; W M A Verhoeven; S Tuinier; J I M Egger; C M van Duijn
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

6.  Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study.

Authors:  Peter P Zandi; James C Anthony; Ara S Khachaturian; Stephanie V Stone; Deborah Gustafson; JoAnn T Tschanz; Maria C Norton; Kathleen A Welsh-Bohmer; John C S Breitner
Journal:  Arch Neurol       Date:  2004-01

7.  Urinary uric acid and antioxidant capacity in children and adults with Down syndrome.

Authors:  Carlos Campos; Rodrigo Guzmán; Encarnación López-Fernández; Angela Casado
Journal:  Clin Biochem       Date:  2009-09-26       Impact factor: 3.281

Review 8.  The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches.

Authors:  Carl W Cotman; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

9.  Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.

Authors:  Virginie Rhein; Xiaomin Song; Andreas Wiesner; Lars M Ittner; Ginette Baysang; Fides Meier; Laurence Ozmen; Horst Bluethmann; Stefan Dröse; Ulrich Brandt; Egemen Savaskan; Christian Czech; Jürgen Götz; Anne Eckert
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

Review 10.  The ets gene family.

Authors:  K Macleod; D Leprince; D Stehelin
Journal:  Trends Biochem Sci       Date:  1992-07       Impact factor: 13.807

View more
  23 in total

1.  Age effects on cortical thickness in young Down's syndrome subjects: a cross-sectional gender study.

Authors:  Andrea Romano; Marta Moraschi; Riccardo Cornia; Alessandro Bozzao; Olga Gagliardo; Laura Chiacchiararelli; Cristina Iani; Giacomo Stella; Giorgio Albertini; Alberto Pierallini
Journal:  Neuroradiology       Date:  2015-01-06       Impact factor: 2.804

Review 2.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

Review 3.  HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.

Authors:  Eugenio Barone; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2016-11-10       Impact factor: 7.376

Review 4.  Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome.

Authors:  Alessandra C Martini; Thomas J Gross; Elizabeth Head; Mark Mapstone
Journal:  Neuron       Date:  2022-04-25       Impact factor: 18.688

5.  Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome.

Authors:  Eduardo B Parisotto; Verónica Vidal; Susana García-Cerro; Sara Lantigua; Danilo Wilhelm Filho; Emilio J Sanchez-Barceló; Carmen Martínez-Cué; Noemí Rueda
Journal:  Neurochem Res       Date:  2016-07-23       Impact factor: 3.996

6.  Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model.

Authors:  Faycal Guedj; Ashley E Siegel; Jeroen L A Pennings; Fatimah Alsebaa; Lauren J Massingham; Umadevi Tantravahi; Diana W Bianchi
Journal:  Am J Hum Genet       Date:  2020-10-23       Impact factor: 11.025

7.  Oxidative Stress and Mitochondrial Dysfunction in Down's Syndrome: Relevance to Aging and Dementia.

Authors:  Pinar E Coskun; Jorge Busciglio
Journal:  Curr Gerontol Geriatr Res       Date:  2012-04-29

Review 8.  The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development.

Authors:  E Torac; L Gaman; V Atanasiu
Journal:  J Med Life       Date:  2014 Oct-Dec

9.  Oxidative Stress -a Phenotypic Hallmark of Fanconi Anemia and Down Syndrome: The Effect of Antioxidants.

Authors:  H T El-Bassyouni; H H Afifi; M M Eid; R M Kamal; H H El-Gebali; Gsm El-Saeed; M M Thomas; S A Abdel-Maksoud
Journal:  Ann Med Health Sci Res       Date:  2015 May-Jun

10.  Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress.

Authors:  Panagiotis Zis; Patrick McHugh; Andrew McQuillin; Domenico Praticò; Mark Dickinson; Sima Shende; Zuzana Walker; Andre Strydom
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.